Bictegravir/emtricitabine/tenofovir alafenamide
Sponsors
Midland Research Group, Inc., Thomas Jefferson University, University of Nebraska, Vancouver Infectious Diseases Centre, Azienda Ospedaliera Universitaria Senese
Conditions
Drug UseHIV-1-InfectionHIV-1-infectionHIV/AIDSHuman Immunodeficiency VirusHuman Immunodeficiency Virus I Infection
Phase 2
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Active, not recruitingNCT06544733
Start: 2024-08-20End: 2029-06-30Target: 675Updated: 2026-01-05
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
TerminatedNCT06613685
Start: 2024-10-21End: 2026-03-16Updated: 2026-03-31
Phase 3
Phase 4
Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1
CompletedNCT03502005
Start: 2018-03-01End: 2019-12-30Updated: 2024-09-19
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
CompletedNCT03998176
Start: 2019-10-09End: 2022-04-01Updated: 2023-10-04
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
NCT04132674
Start: 2018-11-26End: 2020-12-31Target: 40Updated: 2019-10-21
Unknown Phase
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients
CompletedNCT03789968
Start: 2019-09-01End: 2020-10-05Updated: 2020-10-08
Advanced HIV: Outcomes for Rapid ART
NCT05526118
Start: 2022-08-30End: 2025-01-15Target: 50Updated: 2022-09-02